Incidence trends for twelve cancers in younger adults-a rapid review.

Introduction

Growing evidence suggests that younger patients with cancer are more likely to experience a diagnostic delay. As cancer is more common in the elderly, doctors are more inclined to suspect cancer in older patients [ 1 ] and younger patients are more likely than older people to have consulted with a doctor three or more time before referral [ 2 , 3 ]. Even when referred, younger patients may be referred through a less urgent route compared to older ones [ 4 ]. A delay in diagnosis may result in cancer progressing to a less curable stage. Some studies suggest that for some cancers younger patients have more advanced disease at diagnosis compared to older ones [ 5 , 6 ].

Clinical guidelines for cancer referral are based on the positive predictive value of symptoms, which indicates the likelihood that a certain symptom or symptom’s combination may be caused by cancer. As cancer incidence increases with age, this positive predictive value is higher in older patients. Therefore, many clinical guidelines, such as the UK NICE guidelines for cancer recognition and referral ( https://www.nice.org.uk/guidance/ng12 ), use age as a key criterion to determine which patients require urgent investigation for suspected cancer.

Several recent reports have suggested that colorectal cancer is becoming more common in younger patients. For example, a global study found an increase in the incidence of colorectal cancer in adults under 50 years of age in 19 out of the 36 countries examined, nine of which had a stable or declining pattern in older adults [ 7 ]. Although similar changes have been described in other types of cancer [ 8 ], the data are more limited and there is a lack of comprehensive reviews of the evidence. An increase in the incidence of cancer in younger patients may mean that the predictive value of symptoms may be higher than previously estimated. Referral guidelines may therefore require revision, to avoid younger people experiencing greater diagnostic delays and consequent later stage at diagnosis and less treatable disease.

The aim of this rapid review is to collate and summarise recent epidemiological data on the incidence trends of twelve types of cancer in younger adults to inform and underpin health policy and help address age-related inequalities in cancer diagnosis.

Methods

Search strategy

In August 2020, we searched Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily 1946 to August 19, 2020, Embase Classic+Embase (Ovid) 1947 to 2020 August 20, Science Citation Index-Expanded (Web of Science) 1900-present, Social Sciences Citation Index (Web of Science) 1900-present and Emerging Sources Citation Index (Web of Science) 2015-present to identify studies describing trends in cancer incidence in younger patients. The search included subject headings, text-words, and their synonyms for the search concepts of the cancers of interest, young and middle-aged adults, and change in incidence or prevalence. The searches were limited to studies published from 1995 onwards. Non-English language reports, editorials, letters, and case reports (but not retractions) were removed. Searches were peer-reviewed by a second information specialist. Complete search strategies are listed in the Supplementary Methods. Additional studies were sought by manually checking the references of papers that were identified through the initial literature search. All records were stored in an EndNote™ library, where duplicates were removed, before transferring to Rayyan© software for abstract screening.

Eligibility criteria

We included in the search the twelve adult cancers that have a minimum age threshold for investigation in the UK NICE cancer referral guidelines: colorectal, bladder, lung, oesophagus, pancreas, stomach, breast, ovarian, uterine, kidney, and laryngeal cancer and myeloma. ‘Younger cancer patients’ were defined as individuals diagnosed below the age threshold in the NICE guideline for the specific cancer under consideration (Supplementary Table 1 ). Paediatric patients (<18-year olds) were excluded.

Other inclusion criteria were: (1) Language: English; (2) Period: 1995–2020; (3) Setting: OECD country, to have comparable populations in terms of average age, risk factors and lifestyle; (4) Type of study: reporting incidence trend over time in ‘younger patients’ (as defined above) separate from other age groups; (5) Outcome: a quantitative measure of change in incidence over time such as annual percentage change (APC), Average APC (AAPC) or Estimated APC (EAPC), obtained from a modelling approach such as joinpoint regression or age–period–cohort models.

Exclusion criteria were: (1) studies on secondary cancers or metastasis; (2) studies looking only at cancers in limited patient subgroups, for example, those with specific cancer syndromes or immune disorders; (3) studies examining single histological or pathological subtypes; (4) studies reporting trends in graphical format only, as extrapolation or secondary analysis of data was beyond the scope of this review; (5) studies not including at least 5 years of data after 1995; (6) editorials, case-report, expert opinion, studies only published as abstract.

Data collection

Titles and abstracts were screened independently by two authors to determine eligibility. Studies for which there was disagreement between reviewers were included for full-text screening. This was conducted by one of five of the study authors. Where a full-text article was excluded by an author, eligibility was assessed by another author and disagreements resolved through discussion. Reasons for exclusion were recorded. Data extraction was undertaken with a predesigned template (Supplementary Methods).

Assessment of quality of evidence

The quality of the studies was assessed using the Joanna Briggs Checklist for prevalence studies ( https://jbi.global/critical-appraisal-tools ), assigning a score of one for each of the criteria met.

Synthesis

Findings were summarised using a narrative synthesis and presented visually in the form of tables and figures for each cancer type. For colorectal and breast cancer, random-effects meta-analysis was used to derive pooled estimates of the APCs and forest plots for graphical visualisation of results. Pooled estimates were calculated for studies reporting trends for similar age groups if there were at least three studies per age group. Further details of this analysis are reported in Supplementary Methods. When a study reported an APC for more than one period, only the most recent trend was considered.

Results

Search results

We identified 1503 references through database searches and 41 from manual reference checks, with 225 progressing to the full-text screen. Ninety-eight studies satisfied all the inclusion criteria and were selected for the review (Fig. 1 ). Fig. 1 Review PRISMA flow diagram. The final number of articles included in the review was 98. A total of 2388 references were identified from Embase, MEDLINE and Web of Science. After the removal of duplicates, 1503 abstracts were assessed for eligibility. Of these, 225 were progressed to full-text assessment, along with other 41 publications identified through manual reference screening. After full-text review, 98 articles were identified as eligible, whilst 127 references were excluded.

All studies had a retrospective design and were based on national or local cancer registries. Sixty-eight studies originated from North America, 24 from Europe, 3 from Oceania, 2 from Asia and 1 from South America. Five studies compared several countries worldwide.

Most studies contributed data for one type of cancer, but eight provided data for two or more. The most represented cancers were colorectal and breast. The quality of the studies was generally good, with a mean score of 8 (range 6–9), and 78 out of 98 studies scored 8 or above, out of the maximum possible score of 9. A list with details of the included studies is available in Supplementary Table 2 .

Cancer trends in younger adults

For some cancers, there was a clear and reproducible trend towards either an increase or a decrease in younger patients. For others, the studies included in the review reported conflicting results and no conclusion could be drawn on whether their incidence is changing, and in which direction. Based on this, we identified three distinct groups of cancers: those with consistent evidence of rising incidence in younger age groups (colorectal, breast, pancreas, kidney and uterine cancers), those with consistent evidence of decreasing incidence in younger age groups (bladder, lung and laryngeal cancer), and those for which the data were deemed inconclusive (stomach, oesophageal, ovarian cancer and myeloma) (Table 1 ). For the cancers with a clear trend towards an increase or a decrease, we considered the evidence ‘strong’ when coming from more than ten good-quality studies and ‘moderate’ when coming from ten or less good-quality studies. Table 1 Overview of recent cancer incidence trends in younger adults. Cancer type Number of studies Countries Overall Incidence trend Strength of evidence Cancers with consistent evidence of a rise in younger adults Colorectal 43 International (5), US (24), Canada (5), Australia (2), Italy (2), England (2), Denmark (1), Sweden (1), Republic of Ireland (1) Significant increase in aged <50 years, especially the youngest subgroups (i.e. aged <30 years), in both genders and both colon and rectal subtypes, with a declining trend in those aged >50 years. The trend is observed in most wealthy countries worldwide, with some geographical variation in Europe. Strong Breast 28 US (14), Canada (3), Netherlands (2), France (1), Germany (1), Spain (1), Portugal (1), Switzerland (1), Colombia (1), more than one European country (3) Small but significant increase in women aged <50 years in a wide range of OECD countries. Strong Kidney 10 US (7), Canada (3) General increase in all age groups in North America, with evidence of a greater increase in those aged <45 years. Moderate Uterus 9 US (4), Canada (2), England (1), Norway (1), New Zealand (1) Significant increase in women of all ages but evidence of a more pronounced rise in those aged 30–50 years in some countries. Moderate Pancreas 9 US (7), Canada (2) Recent increase in those aged <40 years in North America, with some evidence of a more pronounced increase in women than in men. Moderate Cancers with a consistent evidence of decline in younger adults Lung 9 US (6), Canada (2), Spain (1) Decrease in all age groups, but especially in younger ages (i.e. 30–50 years of age) and more pronounced in men than women. Moderate Bladder 6 US (4), Canada (2) General decrease in all age groups with evidence of a steeper decrease in those aged <45 years. Moderate Laryngeal 6 US (2), Canada (2), the Netherlands (2) General decrease, with evidence of a steeper decrease in younger age groups (<50 years of age). Moderate Cancers with inconclusive evidence Stomach 11 US (8), Canada (2), South Korea (1) Decrease in those aged >50 years; conflicting evidence for those aged <50 years with a possible increase in the non-cardia adenocarcinoma subtype. Inconclusive Oesophagus 9 US (6), Canada (2), France (1) Conflicting evidence but possible increase in adenocarcinomas and decrease in squamous cell carcinomas in those aged <50. Inconclusive Ovarian 7 US (3), Canada (2), South Korea (1), International (1) Decrease in women aged >40 years; either stable or decreasing trend in younger women in most OECD countries, but an increase in Asia. Inconclusive Myeloma 4 US (2), Canada (2) Some evidence of increase in all ages, but particularly patients aged <50 years in US; contrasting evidence in Canada. Inconclusive Cancer type, the total number of studies contributing evidence for each cancer, the countries where the studies were based and overall trend is reported. Cancers were divided based on whether the studies included in the review demonstrated a clear and consistent trend towards an increase or decrease in incidence. The strength of the evidence was considered ‘strong’ when coming from a large number of good-quality studies (>10) and ‘moderate’ when coming from a smaller number of good-quality studies (10 ore less).

Cancers with evidence of an increase in younger age groups

Colorectal cancer

Forty-three studies reported trends in the incidence of colorectal cancer in patients aged under 50 years (Table 1 and Fig. 2 ). Four of them examined international databases and described an increase in incidence in this age group in a wide range of wealthy countries worldwide, often accompanied by a decreasing incidence in those aged 50 and over [ 7 , 9 – 11 ]. Fig. 2 Recent trends in the incidence of colorectal cancer. Annual percentage changes (APC) in incidence are reported by age group. Increases are indicated in red and decreases in blue, with darker colours corresponding to greater changes. Stable incidences are indicated in white. For simplicity, the unstratified APC is reported, when available. For studies where the unstratified APC was not available, APC is stratified by anatomical location, histological type, gender and/or two main ethnicities (Black and NHW, non-Hispanics White). When APC values were available for several time periods, only the most recent APC is included. For some studies, the upper age limit for the oldest group and the lowest age limit for the younger group were not reported in the original study. Detailed information of the time periods and age groups covered by the different studies is reported in Supplementary Table 2 . The following references are not included in the figure as they cover a large number of countries: Lu et al. [ 9 ] (20 countries worldwide), Siegel et al. [ 7 ] (36 countries worldwide).

Twenty-nine studies looked at colorectal cancer incidence in North America [ 7 – 39 ] and all except two [ 16 , 34 ] found a significant increase in the under 50s, of generally comparable magnitude in both men and women, with a corresponding decrease in older-age groups. APCs in younger patients were in the ranges of 1–3% when these were considered as a single group. When further subdivided by age and gender, the largest increase was observed in the youngest subgroups [ 8 , 12 , 15 , 23 , 28 , 30 , 33 ]. This was particularly so in Canada, where APCs of 6–7% were reported in under 30s [ 35 – 39 ], which are larger than the rise observed in the US in the same age group. One US study [ 24 ] found a stable rate of colon cancer in younger patients, but a rising rate of rectal cancer in the same age group. Data from other studies [ 14 , 17 , 20 , 28 – 30 ] also suggested that the increase in colorectal cancer in the US may be driven predominantly by rectal tumours. In Canada, however, inconsistent results were found regarding anatomical location, with some studies showing a larger increase in colon and others in rectal cancers.

In Europe, large increases are observed in the younger population, with an annual rise between 2004 and 2016 of 7.9% in 20–29-year olds, 4.9% in 30–39-year olds and 1.6% in 40–49-year olds [ 40 ]. Some heterogeneity is noticeable between European countries with clear evidence of a rise in the under 50s in the UK [ 7 , 9 – 11 , 40 – 42 ] and Denmark [ 7 , 9 , 11 , 40 , 43 ] but a stable incidence in other countries.

In Australia, a similar increase in under 50s, especially the younger subgroups, and a corresponding decrease in over 50s was reported [ 7 , 9 – 11 , 44 , 45 ]. In one study [ 45 ], the increase in under 50s was only statistically significant in women. Data from New Zealand were less consistent. Whilst an increased incidence of colorectal cancer in younger patients (APC 2.9–4.0) was observed in two international comparisons [ 7 , 11 ], a third study [ 9 ] recorded no changes in young males and a small decrease of colon cancer in young females, together with a small increase in rectal cancer. We found one study including data from Asia [ 10 ], confirming a decrease in incidence in over 50 and an increase in under 50 in Japan.

Meta-analysis of studies with similar age group subdivision confirms an overall increase in patients below 50 years of age (pooled APC: 1.57, CI: 1.08–2.06), especially those in younger subgroups (pooled APC 20–29-year olds: 6.24, 95% CI: 4.79–7.69; pooled APC 30–39-year olds: 4.27, 95% CI: 2.98–5.56) (Supplementary Table 3 and Supplementary Fig. 2a–c ).

Noticeably, some of the studies suggest that younger colorectal cancer patients often present with more aggressive diseases than older ones [ 23 , 25 , 43 ] and that the recent increase in incidence in younger patients is driven by more invasive cancers [ 13 – 15 , 31 – 34 , 46 , 47 ]. For example, one study [ 47 ] reported that the proportion of patients under 50 presenting with Stage 4 colorectal cancer in the Republic of Ireland has doubled in recent years, from 11% in 1994 to 23% in 2012.

Breast cancer

We identified 28 publications reporting incidence trends of breast cancer in younger women (Table 1 and Fig. 3 ) [ 8 , 26 , 27 , 37 , 39 , 48 – 70 ]. Fig. 3 Recent trends in the incidence of breast cancer. Annual percentage changes (APC) in incidence are reported by age group. Increases are indicated in red and decreases in blue, with darker colours corresponding to greater changes. Stable incidences are indicated in white. For simplicity, the unstratified APC is reported, when available. For studies where the unstratified APC was not available, APC is stratified by gender and/or two main ethnicities (Black and NHW, non-Hispanics White). When APC values were available for several time periods, only the most recent APC is included. For some studies, the upper age limit for the oldest group and the lowest age limit for the younger group were not reported in the original study. Detailed information of the time periods and age groups covered by the different studies is reported in Supplementary Table 2 .

Almost all North-American studies found a recent increase in incidence in women under 50 [ 26 , 27 , 37 , 39 , 48 – 50 , 53 – 56 , 59 ], with only four studies reporting no change [ 8 , 51 , 52 , 57 ] and one reporting a decrease in women of black ethnicity [ 58 ]. The magnitude of the change was modest, generally in the order of 0.5–1% per year. In some studies, the increase was limited to or more pronounced in the youngest subgroups [ 37 , 39 , 48 , 49 , 54 , 59 ]. Several studies reported a significant decrease in older women (i.e. over 50) [ 8 , 51 , 55 – 57 ]. Some studies suggested that the observed increase in breast cancer in younger women in North America may be driven by invasive tumours [ 26 , 27 , 56 ]. For example, Johnson et al. reported no change in localised and regional disease but a strong increase in distal disease in women under 40 [ 56 ].

Eight out of the ten European studies also reported an increase in incidence in women under 50 [ 61 – 63 , 65 – 69 ] with two finding no statistical change [ 60 , 64 ]. In Portugal, the magnitude of change was larger than observed in the US and Canada, with APC around 2.7 [ 63 , 66 ], but for the other countries the observed increase was ~1–2% per year.

The single South American study reports a similar increased risk of breast cancer in under 50 s in Colombia, as well as older-age groups [ 70 ].

Meta-analysis of studies with similar age group subdivision showed a small but significant increase in patients below 50 years of age (pooled APC: 0.94, 95% CI: 0.06–1.82). The larger increase was found in women aged 20–29 years (pooled APC: 2.45, 95% CI: 1.41–3.49) (Supplementary Table 3 and Supplementary Fig. 3 ).

Kidney cancer

For kidney cancer, we found ten eligible studies, all from North America (Table 1 and Fig. 4a ) [ 8 , 26 , 27 , 37 , 39 , 71 – 75 ]. They consistently show a recent increase in the incidence of kidney cancer in all ages and in both genders, with six detecting a steeper rise in younger compared with older-age groups [ 8 , 26 , 37 , 39 , 71 , 72 ]. The annual increase in patients under 45 varied between 0.9 and 7.9% depending on the study, period considered and age grouping. Fig. 4 Other cancers with increasing incident trend in younger adults. Annual percentage changes (APC) in incidence of kidney ( a ), uterine ( b ) and pancreatic ( c ) cancer are reported by age group. Increases are indicated in red and decreases in blue, with darker colours corresponding to greater changes. Stable incidences are indicated in white. For simplicity, the unstratified APC is reported, when available. For studies where the unstratified APC was not available, APC is stratified by gender and/or two main ethnicities (Black and NHW, non-Hispanics White). When APC values were available for various time periods, only the most recent APC is included. For some studies, the upper age limit for the oldest group and the lowest age limit for the younger group were not reported in the original study. Detailed information of the time periods and age groups covered by the different studies is reported in Supplementary Table 2 .

Uterine cancer

Of the nine studies including incidence trends for uterine cancer in women under 55 [ 8 , 26 , 27 , 37 , 39 , 76 – 79 ], seven reported an increase (Table 1 and Fig. 4b ).

In Canada, the rise was observed in women of all ages [ 37 , 39 ], whilst in the US it was more pronounced in the under 50s, and especially in the 30–39 age group [ 8 , 26 , 27 ]. One study found a trend to an increase that became non-significant after adjusting for hysterectomy rates [ 76 ].

In Europe, an increase was observed in England in women 45–55-years old with a comparable increase in older women [ 78 ]. In Norway, there was a trend towards an increase in both women under and above 55 years of age, but it was significant only in the older group [ 77 ].

Compared to other countries, the largest increase was observed in New Zealand, where a study reported an APC of 9.22 (95% CI 6.10–12.50) in women <40 between 1996 and 2012, whilst the rise was smaller in older women [ 79 ].

Pancreatic cancer

All nine studies including trends in incidence of pancreatic cancer in patients below 60 originated from North America (Table 1 and Fig. 4c ) [ 8 , 19 , 26 , 37 , 39 , 80 – 83 ]. Taken together, these papers suggest a general increase in rates of pancreatic cancer in all age groups starting in 1940/50s with a peak in the 1970s/1980s, followed by stabilisation or decrease from 1975 onwards.

However, several studies detected a recent increase, particularly in younger adults aged under 40 [ 8 , 26 , 37 , 39 , 81 , 82 ]. In Canada, the increase in younger groups was accompanied by a corresponding decrease in the over 50s [ 37 , 39 ]. In two US studies, the increase in the younger age groups was specific to women, whilst in men the rise was only observed in the over 55 [ 26 , 81 ]. In a Canadian study, however, the increase was more marked in younger men than women [ 39 ].

Cancer with evidence of a decline in younger adults

Lung cancer

Of the nine studies meeting the inclusion criteria for lung cancer [ 8 , 26 , 27 , 37 , 39 , 84 – 87 ], the majority reported a decline across all ages, but especially in under 40s, with annual changes of up to −6.5% (Table 1 and Fig. 5a ). Two publications reported a small increase in older patients (>70) [ 8 , 37 ]. The only discordant result was from a Spanish study, which reported no significant change in young men, but a large increase in young women [ 87 ]. When under-40s were further stratified in smaller age groups, a decrease was often reported in the older subgroups (i.e. 30–40-year olds) but not in the younger (i.e. <30-year olds). When data were stratified by gender, a more pronounced decrease was observed in men compared with women. Fig. 5 Cancers with decreasing incidence trend in younger adults. Annual percentage changes (APC) in incidence of lung ( a ), bladder ( b ) and laryngeal ( c ) cancer are reported by age group. Increases are indicated in red and decreases in blue, with darker colours corresponding to greater changes. Stable incidences are indicated in white. For simplicity, the unstratified APC is reported, when available. For studies where the unstratified APC was not available, APC is stratified by gender and/or two main ethnicities (Black and NHW, non-Hispanics White). When APC values were available for various time periods, only the most recent APC is included. For some studies, the upper age limit for the oldest group and the lowest age limit for the younger group were not reported in the original study. Detailed information of the time periods and age groups covered by the different studies is reported in Supplementary Table 2 .

Bladder cancer

We found six studies with data on incidence for bladder cancer in the under 45s, all from North America (Table 1 and Fig. 5b ) [ 8 , 26 , 37 , 39 , 88 , 89 ]. After an initial rise in the 1970s/80s, a consistent decrease was observed in recent decades in all age groups. In four studies the decrease was slightly more pronounced in younger compared to older-age groups [ 8 , 37 , 39 , 88 ]. For patients under 45, recent annual changes in incidence varied from −1.0 to –2.7%.

Laryngeal cancer

The six studies including data on incidence trends for laryngeal cancer in patients under 45 show an overall decrease in incidence (Table 1 and Fig. 5c ) [ 8 , 37 , 39 , 90 – 92 ]. In four studies, the decline was steeper in younger age groups [ 8 , 37 , 91 , 92 ]. However, a small increase in 20–29-year olds was observed in one publication [ 36 ]. Two studies reported an increased incidence in women over 60 [ 91 , 92 ].

Cancers with the unclear trend in younger adults

Stomach cancer

Eleven studies reported changes in incidence in stomach cancer in patients below 55 (Table 1 and Supplementary Fig. 1a ) [ 8 , 19 , 26 , 37 , 39 , 93 – 98 ].

Six studies examined stomach cancer as a single entity, without subdivision in subtypes [ 19 , 26 , 37 , 39 , 96 , 98 ]. These studies showed a decrease in older-age groups with some detecting a stable or increased rate in younger patients. APCs for people under 55 were variable, with positive and negative values reported in different studies.

Some US studies stratified stomach tumours based on the two major anatomical subtypes. In under-55s, rates of cancer of the gastric cardia were found to be stable [ 8 , 93 ], whilst a trend to an increase was observed for non-cardia adenocarcinomas, with a corresponding decrease in older groups [ 8 , 93 , 95 , 97 ].

Oesophageal cancer

Nine studies met inclusion criteria for oesophageal cancer (Table 1 and Supplementary Fig. 1b ) [ 8 , 19 , 37 , 39 , 90 , 93 , 95 , 99 , 100 ].

Four of these studies grouped all types of oesophageal cancer types together, with contrasting results [ 19 , 37 , 39 , 100 ]. In Canada, one study [ 37 ] observed an increase in the incidence of oesophageal cancer between 1983 and 2001, particularly in younger adults, whilst another [ 39 ] reported a decrease in under-40s. In France, a strong decrease in men aged 25–44 was found in the same time period, with a reduction of incidence in men born in the 1970s compared to those born in the 1940s [ 100 ]. A decrease in oesophageal cancer was also found in the US in all age groups, especially in adults under 50 [ 19 ].

Five studies examined trends for oesophageal squamous cell carcinoma and adenocarcinoma separately [ 8 , 90 , 93 , 99 ]. For squamous cell carcinoma, a general decrease in incidence was observed in all studies, although in one study [ 99 ] this was only significant in over 45s, whilst in another [ 8 ] it was more pronounced in 35–44-year olds. For adenocarcinoma, two studies [ 93 , 95 ] found an increase in under 50s, whilst another two [ 8 , 99 ] found no significant change in younger groups.

Ovarian cancer

Seven papers included age-specific trends in ovarian cancer incidence in women under 50 (Table 1 and Supplementary Fig. 1c ) [ 8 , 26 , 27 , 37 , 39 , 101 , 102 ].

One study [ 101 ] examined international trends in 27 countries and showed that incidence rates in all age groups have decreased over time in most high-income countries since the 1990s, with exception of Japan and Korea where a significant increase has been observed in older women [ 101 , 102 ].

In Canada, one study [ 37 ] reported a significant decrease in women of all ages, except 20–24 and 80–84-year olds, whilst another [ 39 ] found a decline in most ages except 40–49-year olds, where the rate was stable, and 20–29-year olds where a significant increase was noticed.

In US, one publication [ 26 ] reported a significant decrease in all women above 40, but no change in the 25–39 age group. Similarly, another study [ 8 ] found a decrease in all age groups above 35, but no significant change in those under 35. However, a third study [ 27 ] found an overall significant decrease in women aged 20–49.

Myeloma

The four studies with data on myeloma were based in North America (Table 1 and Fig. 4d ) [ 8 , 26 , 37 , 39 ]. Both studies from the US reported an increase in all age groups but particularly under 50s, with APC increasing inversely to age [ 8 , 26 ].

The two studies from Canada had contrasting results. In one study, a significant increase was observed in males aged 40–59 years and older but not 20–39-year olds and a decrease was found in 30–39-year-old women [ 39 ]. A second Canadian study reported no significant increase in those aged under 55 years but a small increased in older ages [ 37 ].

Discussion

This is the first review examining epidemiological evidence across a range of twelve cancers with age-related referral criteria, to determine whether their incidence is increasing in younger patients. Previous reviews have generally focused on single cancers, and mostly on cancers with extensive data of an increase in young adults, such as colorectal [ 103 ]. Our findings show, importantly, that the incidence of colorectal, breast, pancreatic, kidney, and uterine cancer in younger people is rising, whilst the incidence of bladder, laryngeal and lung cancer is decreasing. Contrasting evidence was found for oesophageal, stomach and ovarian cancer and myeloma.

The reasons behind the observed trends are unclear. Changes in the prevalence of lifestyle associated risk factors in high-income countries may be contributing to the trends. Obesity, which has become more prevalent in high-income countries in the last few decades, is a risk factor for four out of the five rising cancers (colorectal, pancreas, kidney, and uterine cancer), whilst its role in early onset breast tumours is more controversial [ 54 , 66 ]. Variations in patterns of childbearing and breastfeeding or increase use of oral contraception may be contributing to the rise in breast and uterine cancer incidence in younger generations [ 67 ]. Three cancers linked to smoking (lung, laryngeal and bladder) show a clear reduction of incidence, in line with the decrease in smoking rates in younger adults in recent decades. Another smoking-linked cancer, oesophageal squamous cell carcinoma, also had some evidence of decrease in younger age groups.

Changes in clinical practice, such as increased diagnostic activity, introduction of cancer screening programmes, change in management of other conditions, or change in disease classification, may have also contributed to the observed changes in incidence. Although colorectal and breast cancer screening is generally targeted to patients over 50 [ 104 , 105 ], in some countries such the US screening may also be available to younger individuals, particularly those with a pertinent family history. A recent study, for example, reported that in the US up to 5% of individuals aged 40–49 had received a colonoscopy in the previous year, and that this proportion has been steadily growing from 2000 to 2015 [ 33 ]. Screening of asymptomatic individuals may result in ‘over-diagnosis’, i.e. detection of indolent tumours, which would have not progressed to become clinically significant. Therefore, an apparent increase in cancer incidence may result from increased screening. However, the increase in breast and colorectal cancer incidence is observed in individuals as young as 20–25-year old, who are unlikely to undergo screening even with a family history of the disease, and it is consistently described across a number of high-income countries worldwide, despites different health delivery systems and screening policies. In addition, some studies reported a specific increase in invasive and late-stage disease in younger age groups, rather than the rise in indolent and early-stage tumours that would be expected if the trends was solely due to increased screening.

A spike in incidence of kidney cancer in all age groups was observed in the 80s/90s due to increased imaging and incident detection of benign lesions during scans performed for other indications [ 72 , 75 ]. However, a UK study looking at a range of malignancies found that overdiagnosis only partially explains the increase in kidney cancer since the 1970s [ 106 ]. The fact that the more recent rise is specific to younger patients, especially those under 40, suggests that other mechanisms may also be at play. On the contrary, the same study shows that the apparent increase in uterine cancer in the UK is likely to be driven by overdiagnosis, possibly as result of a recent change in classification guidelines [ 106 ]. A decline in use of hysterectomies for the treatment of other conditions may also have resulted in an increase in the number of uterine cancers [ 76 ].

Establishing the causes for the changes in incidence may require a detailed analysis of the mortality trends. For cancer with poor prognosis and no recent improvement in therapy, an increase in mortality is expected to follow a true increase in incidence rates, whilst increased incidence with stable or declining mortality would suggest overdiagnosis [ 106 ]. Another approach, taken by several studies included in the review, is to employ age–period-cohort modelling to disentangle trends due to factors that influence all ages (period effects), such as changes in clinical practice, those that vary by generation (cohort effects), such as exposure to risk factors, and those due to increasing age (age effects). Taken together the results of this approach suggest a real generational effect for colorectal, kidney and uterine cancers, in addition to the variations attributable to changes in clinical practice or detection of indolent tumours [ 8 , 11 , 30 , 37 , 38 , 44 , 74 , 77 , 78 ], whilst data were less clear for breast and pancreatic cancer [ 8 , 37 , 39 , 54 , 59 , 67 , 70 ].

Strengths and limitations

One of the strengths of our study is the systematic approach and rigorous methodology in the literature search, selection and appraisal of evidence and data extraction. All included studies were of good quality. Most used data from large national registries, with good cover of the reported geographical area and rigorous diagnostic case ascertainment, often including microscopic confirmation. Another strength is that this study comprehensively examines and summarises incidence trends for all twelve cancers for which there are age-based criteria in the UK NICE cancer referral guidelines. Other cancers, such as melanoma, testicular and thyroid cancer are more frequently diagnosed at younger ages and therefore have no age-based criteria for referral. We focussed specifically on those cancers for which younger symptomatic patients may risk a diagnostic delay because of their age. Furthermore, our study defines ‘early on-set’ based on the specific age threshold for investigation for each cancer as reported in these clinical guidelines, rather than using an arbitrary age cut-off for all cancers (e.g., 50). Although clinical guidelines may vary between countries, NICE was chosen as it is a longstanding evidence-based national guideline with widespread adoption. The thresholds for investigation in the NICE guidelines are set at a risk of cancer of 3% or above, regardless of tumour type, resulting in different age thresholds between cancers.

One of the limitations of the study is that, to facilitate comparison, we included only publications that reported annual percentage changes in incidence. Therefore, we may have omitted some relevant studies which used other types of measures such as incidence ratios. Despite this, there was still some heterogeneity between studies, in terms of period covered, subdivision in age groups, stratification for gender and/or ethnicity or subdivision into specific anatomical, pathological or histological subtypes. Therefore, comparisons between studies need to be interpreted with caution. However, for some cancers, there was a very strong agreement between studies regarding the direction and magnitude of change. Due to this heterogeneity, meta-analysis was only possible for a subset of colorectal and breast cancer studies with similar age subdivisions. The results confirmed a significant incidence increase for both cancers in the younger age groups.

Most studies included in the review were based in North America so generalisability to other settings is uncertain, although trends were relatively consistent across countries particularly for the cancers with a larger amount of literature available. Our search used three comprehensive databases (Embase, Medline and Web of Science) but it is possible that searching different databases could have uncovered more studies from the under-represented countries, published in journals not indexed by the resources we searched.

One of the limitations of registry studies is the lack of granularity in the data. Most studies did not have information regarding patient’s risk factors, socio-economic background or comorbidities, although some US studies stratified for ethnicity. For colorectal cancers, the most consistent increase was observed in the non-Hispanic White population [ 14 , 16 , 27 , 28 , 32 ], although some studies also detected an increase in Hispanic or Black ethnicities [ 21 – 23 ]. For breast cancer, the most significant changes were seen in young women of Asian/Pacific Islander ethnicity [ 8 , 48 , 50 , 59 ]. Although the evidence for stomach cancer overall was inconclusive, a significant increase in women under 50 of white ethnicity was reported in several studies [ 8 , 93 , 95 , 97 ]. Therefore, stratification based on ethnicity and risk factors may allow to detect significant trends not apparent when younger adults are considered as a single group.

As clinical and screening guidelines group cancers based on their anatomical site, we intentionally avoided considering histological subtypes separately. However, cancer subtypes may have different aetiology and therefore distinct incidence patterns that may not become apparent when analysed as a single group. Indeed, some of the studies included in this review indicate that, whilst oesophageal squamous cell carcinoma is generally decreasing in incidence, adenocarcinoma may be increasing in under 50s. Therefore, stratification for histological subtype may reveal changes in incidence that were not apparent in our analysis.

Clinical implications and future research

The robust evidence of an increase in colorectal cancer incidence in younger people in North America, Europe and Oceania, calls for a re-evaluation of the age threshold for the referral of symptomatic patients. This requires re-assessing the predictive value of symptoms in younger populations and a full health economic modelling to examine the balance of costs and benefits of lowering the referral thresholds. Similarly, lowering the minimum age for eligibility in colorectal cancer national screening programmes may be considered but only after careful weighting of the economic and health service implications. A modelling study in Australia has suggested that lowering bowel cancer screening threshold to 45 may be cost-effective but would increase colonoscopy demand by 3–14% and require 55–170 additional colonoscopies per additional death prevented [ 107 ]. Notably, the US Preventative Services Taskforce recently lowered their age recommendations for bowel screening from 50 to 45 years.

Whilst the increase in breast cancer incidence in young women was consistently reported across Europe and North America, the raise was modest and the overall risk remains low. For cancers with evidence of an increase, additional descriptive studies may be warranted to provide accurate estimates of current and future incidence rates in younger age groups and determine whether the overall risk is sufficiently high to justify a change in guidelines. Further research should also determine the causes behind the rise to disentangle real generational effects to those due to changes in clinical practice, increase testing and overdiagnosis. Policy changes regarding referral of symptomatic patients or screening could be considered in those countries and for those cancers with a confirmed increasing trend. However, despite increases in incidence, the low absolute risk in young people may mean that a change in age thresholds may not be cost-effective or justifiable. Nevertheless, family doctors should be aware of these trends and that the possibility of cancer should not be dismissed solely based on age. Mechanisms should be in place to allow clinicians to take further action if they suspect serious disease in younger patients.

Clarifying the role of preventable causes will help underpin more effective population health policies aimed at cancer prevention. More research is also needed to establish whether the rising incidence trend in the younger population is associated to specific subgroups, to allow improved risk stratification and facilitate more targeted interventions. Furthermore, lowering of referral or screening age may be facilitated by the development of new highly sensitive and specific testing modalities.

In conclusion, our study shows that the incidence of colorectal, breast, kidney, pancreatic and uterine cancer is increasing in younger people, whilst lung, laryngeal and bladder cancers are becoming less common. Policymakers need to be aware of these trends when reviewing guidelines and screening programmes. Addressing preventable risk factors such as excess weight may help curb the increase of these malignancies in younger generations.

Supplementary information

Supplementary legends Supplementary Figure 1 Supplementary Figure 2 Supplementary Figure 3 Supplementary Table 1 Supplementary Table 2 Supplementary Table 3 Supplementary methods

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

The online version contains supplementary material available at 10.1038/s41416-022-01704-x.

Author contributions

EdM conceived and designed the study, acquired the data, interpreted the results and drafted the manuscript; LS contributed to the design of the study, acquisition of the data, meta-analysis and drafting and revision of the manuscript; SHB contributed to the acquisition of data, interpretation of results, and drafting and revision of the manuscript; SH and RB contributed to the acquisition of the data and revision of the manuscript; JW designed and ran the literature searches and revised the manuscript; CR and JE contributed to the interpretation of the results and revised the manuscript; RDN oversaw the work and contributed to the interpretation of the results and revision of the manuscript.

Funding

This research arises from the CanTest Collaborative, which is funded by Cancer Research UK [C8640/A23385], of which RN and JE are Associate Directors, EdM is Research Fellow, SB is Clinical Research Fellow and CR is Principal Clinical Research Fellow. CR is also supported by the CR-UK International Cancer Early Detection Alliance (ACED) award C18081 / A31373 .

Data availability

As the study is a review, data are already publicly available. A spreadsheet containing the data extracted from the 98 studies included in the review is available from the corresponding author on request.

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

Not applicable.

Consent to publish

Not applicable.

References

1. Adam R Garau R Raja EA Jones B Johnston M Murchie P Do patients’ faces influence General Practitioners’ cancer suspicions? A test of automatic processing of sociodemographic information PLoS ONE 2017 12 e0188222 10.1371/journal.pone.0188222 29166652 PMC5699847

2. Mendonca SC Abel GA Lyratzopoulos G Pre-referral GP consultations in patients subsequently diagnosed with rarer cancers: a study of patient-reported data Br J Gen Pr 2016 66 e171 181 10.3399/bjgp16X683977 PMC4758496 26917657

3. Lyratzopoulos G Neal RD Barbiere JM Rubin GP Abel GA Variation in number of general practitioner consultations before hospital referral for cancer: findings from the 2010 National Cancer Patient Experience Survey in England Lancet Oncol 2012 13 353 65 10.1016/S1470-2045(12)70041-4 22365494

4. Arhi CS Ziprin P Bottle A Burns EM Aylin P Darzi A Colorectal cancer patients under the age of 50 experience delays in primary care leading to emergency diagnoses: a population-based study Colorectal Dis 2019 21 1270 8 10.1111/codi.14734 31389141

5. Mauri G Sartore-Bianchi A Russo AG Marsoni S Bardelli A Siena S Early-onset colorectal cancer in young individuals Mol Oncol 2019 13 109 31 10.1002/1878-0261.12417 30520562 PMC6360363

6. Narod SA Breast cancer in young women Nat Rev Clin Oncol 2012 9 460 70 10.1038/nrclinonc.2012.102 22733233

7. Siegel RL Torre LA Soerjomataram I Hayes RB Bray F Weber TK Global patterns and trends in colorectal cancer incidence in young adults Gut 2019 68 2179 85 10.1136/gutjnl-2019-319511 31488504

8. Sung H Siegel RL Rosenberg PS Jemal A Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry Lancet Public Health 2019 4 e137 47 10.1016/S2468-2667(18)30267-6 30733056

9. Lu XQ Li Y Wang W Feng WT Shi OM Wang Q International incidence trends in early- and late-onset colorectal cancer: a population-based study Int J Colorectal Dis 2020 35 1077 86 10.1007/s00384-020-03558-2 32173775

10. Lui RN Tsoi KKF Ho JMW Lo CM Chan FCH Kyaw MH Global increasing incidence of young-onset colorectal cancer across 5 continents: a joinpoint regression analysis of 1,922,167 cases Cancer Epidemiol Biomark Prev 2019 28 1275 82 10.1158/1055-9965.EPI-18-1111 31113868

11. Araghi M Soerjomataram I Bardot A Ferlay J Cabasag CJ Morrison DS Changes in colorectal cancer incidence in seven high-income countries: a population-based study Lancet Gastroenterol Hepatol 2019 4 511 8 10.1016/S2468-1253(19)30147-5 31105047 PMC7617144

12. Ansa BE, Coughlin SS, Alema-Mensah E, Smith SA. Evaluation of colorectal cancer incidence trends in the United States (2000–2014). J Clin Med. 2018;7:22. 10.3390/jcm7020022 PMC5852438 29385768

13. Augustus GJ Roe DJ Jacobs ET Lance P Ellis NA Is increased colorectal screening effective in preventing distant disease? PLoS ONE 2018 13 e0200462 10.1371/journal.pone.0200462 30001362 PMC6042755

14. Austin H Henley SJ King J Richardson LC Eheman C Changes in colorectal cancer incidence rates in young and older adults in the United States: what does it tell us about screening Cancer Causes Control 2014 25 191 201 10.1007/s10552-013-0321-y 24249437 PMC4394895

15. Bailey CE Hu CY You YN Bednarski BK Rodriguez-Bigas MA Skibber JM Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975–2010 JAMA Surg 2015 150 17 22 10.1001/jamasurg.2014.1756 25372703 PMC4666003

16. Cress RD Morris C Ellison GL Goodman MT Secular changes in colorectal cancer incidence by subsite, stage at diagnosis, and race/ethnicity, 1992-2001 Cancer 2006 107 1142 52 10.1002/cncr.22011 16835912

17. Crosbie AB Roche LM Johnson LM Pawlish KS Paddock LE Stroup AM Trends in colorectal cancer incidence among younger adults-Disparities by age, sex, race, ethnicity, and subsite Cancer Med 2018 7 4077 86 10.1002/cam4.1621 29932308 PMC6089150

18. Giddings BH Kwong SL Parikh-Patel A Bates JH Snipes KP Going against the tide: increasing incidence of colorectal cancer among Koreans, Filipinos, and South Asians in California, 1988–2007 Cancer Causes Control 2012 23 691 702 10.1007/s10552-012-9937-6 22460700

19. Hussan H Patel A Le Roux M Cruz-Monserrate Z Porter K Clinton SK Rising incidence of colorectal cancer in young adults corresponds with increasing surgical resections in obese patients Clin Transl Gastroenterol 2020 11 e00160 10.14309/ctg.0000000000000160 32352680 PMC7263654

20. Loomans-Kropp HA Umar A Increasing incidence of colorectal cancer in young adults J Cancer Epidemiol 2019 2019 9841295 10.1155/2019/9841295 31827515 PMC6885269

21. Rahman R Schmaltz C Jackson CS Simoes EJ Jackson-Thompson J Ibdah JA Increased risk for colorectal cancer under age 50 in racial and ethnic minorities living in the United States Cancer Med 2015 4 1863 70 10.1002/cam4.560 26471963 PMC5123715

22. Van Beck KC Jasek J Roods K Brown JJ Farley SM List JM Colorectal cancer incidence and mortality rates among New York City adults ages 20–54 years during 1976–2015 JNCI Cancer Spectr 2018 2 pky048 10.1093/jncics/pky048 31360871 PMC6649822

23. Wang DY Thrift AP Zarrin-Khameh N Wichmann A Armstrong GN Thompson PA Rising incidence of colorectal cancer among young Hispanics in Texas J Clin Gastroenterol 2017 51 34 42 10.1097/MCG.0000000000000563 27956718 PMC5157697

24. Meyer JE Narang T Schnoll-Sussman FH Pochapin MB Christos PJ Sherr DL Increasing incidence of rectal cancer in patients aged younger than 40 years: an analysis of the surveillance, epidemiology, and end results database Cancer 2010 116 4354 9 10.1002/cncr.25432 20734460 PMC3624076

25. Tawadros PS Paquette IM Hanly AM Mellgren AF Rothenberger DA Madoff RD Adenocarcinoma of the rectum in patients under age 40 is increasing: impact of signet-ring cell histology Dis Colon Rectum 2015 58 474 8 10.1097/DCR.0000000000000318 25850833

26. Kehm RD Yang W Tehranifar P Terry MB 40 years of change in age- and stage-specific cancer incidence rates in US women and men JNCI Cancer Spectr 2019 3 pkz038 10.1093/jncics/pkz038 31414075 PMC6686848

27. Ward EM Sherman RL Henley SJ Jemal A Siegel DA Feuer EJ Annual report to the nation on the status of cancer, featuring cancer in men and women age 20–49 years J Natl Cancer Inst 2019 111 1279 97 10.1093/jnci/djz106 31145458 PMC6910179

28. Siegel RL Jemal A Ward EM Increase in incidence of colorectal cancer among young men and women in the United States Cancer Epidemiol Biomark Prev 2009 18 1695 8 10.1158/1055-9965.EPI-09-0186 19505901

29. Siegel R Desantis C Jemal A Colorectal cancer statistics, 2014 CA Cancer J Clin 2014 64 104 17 10.3322/caac.21220 24639052

30. Siegel RL, Fedewa SA, Anderson WF, Miller KD, Ma J, Rosenberg PS, et al. Colorectal cancer incidence patterns in the United States, 1974–2013. J Natl Cancer Inst. 2017;109:8. 10.1093/jnci/djw322 PMC6059239 28376186

31. Siegel RL Miller KD Fedewa SA Ahnen DJ Meester RGS Barzi A Colorectal cancer statistics, 2017 CA Cancer J Clin 2017 67 177 93 10.3322/caac.21395 28248415

32. Siegel RL Miller KD Goding Sauer A Fedewa SA Butterly LF Anderson JC Colorectal cancer statistics, 2020 CA Cancer J Clin 2020 70 145 64 10.3322/caac.21601 32133645

33. Fedewa SA Siegel RL Jemal A Are temporal trends in colonoscopy among young adults concordant with colorectal cancer incidence? J Med Screen 2019 26 179 85 10.1177/0969141319859608 31296103

34. Sheneman DW, Finch JL, Messersmith WA, Leong S, Goodman KA, Davis SL, The impact of young adult colorectal cancer: incidence and trends in Colorado Future Med 2017 6 49 56

35. Patel P De P Trends in colorectal cancer incidence and related lifestyle risk factors in 15–49-year-olds in Canada, 1969–2010 Cancer Epidemiol 2016 42 90 100 10.1016/j.canep.2016.03.009 27060626

36. Brenner DR Heer E Sutherland RL Ruan Y Tinmouth J Heitman SJ National trends in colorectal cancer incidence among older and younger adults in Canada JAMA Netw Open 2019 2 e198090 10.1001/jamanetworkopen.2019.8090 31365108 PMC6669779

37. Heer EV Harper AS Sung H Jemal A Fidler-Benaoudia MM Emerging cancer incidence trends in Canada: the growing burden of young adult cancers Cancer 2020 126 4553 62 10.1002/cncr.33050 32770762

38. Brenner DR Ruan Y Shaw E De P Heitman SJ Hilsden RJ Increasing colorectal cancer incidence trends among younger adults in Canada Prev Med 2017 105 345 9 10.1016/j.ypmed.2017.10.007 28987338

39. Brenner DR Ruan Y Shaw E O’Sullivan D Poirier AE Heer E Age-standardized cancer-incidence trends in Canada, 1971–2015 CMAJ 2019 191 E1262 E1273 10.1503/cmaj.190355 31740536 PMC6861145

40. Vuik FE Nieuwenburg SA Bardou M Lansdorp-Vogelaar I Dinis-Ribeiro M Bento MJ Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years Gut 2019 68 1820 6 10.1136/gutjnl-2018-317592 31097539 PMC6839794

41. Chambers AC Dixon SW White P Williams AC Thomas MG Messenger DE Demographic trends in the incidence of young-onset colorectal cancer: a population-based study Br J Surg 2020 107 595 605 10.1002/bjs.11486 32149386 PMC7155067

42. Exarchakou A Donaldson LJ Girardi F Coleman MP Colorectal cancer incidence among young adults in England: Trends by anatomical sub-site and deprivation PLoS ONE 2019 14 e0225547 10.1371/journal.pone.0225547 31805076 PMC6894790

43. Frostberg E Rahr HB Clinical characteristics and a rising incidence of early-onset colorectal cancer in a nationwide cohort of 521 patients aged 18-40 years Cancer Epidemiol 2020 66 101704 10.1016/j.canep.2020.101704 32234586

44. Feletto E Yu XQ Lew JB St John DJB Jenkins MA Macrae FA Trends in colon and rectal cancer incidence in Australia from 1982 to 2014: analysis of data on over 375,000 cases Cancer Epidemiol Biomark Prev 2019 28 83 90 10.1158/1055-9965.EPI-18-0523 30530848

45. Troeung L Sodhi-Berry N Martini A Malacova E Ee H O’Leary P Increasing incidence of colorectal cancer in adolescents and young adults aged 15–39 years in Western Australia 1982–2007: examination of colonoscopy history Front Public Health 2017 5 179 10.3389/fpubh.2017.00179 28791283 PMC5522835

46. Petersson J Bock D Martling A Smedby KE Angenete E Saraste D Increasing incidence of colorectal cancer among the younger population in Sweden BJS Open 2020 4 645 58 10.1002/bjs5.50279 32484318 PMC7397356

47. Ullah MF Fleming CA Mealy K Changing trends in age and stage of colorectal cancer presentation in Ireland—from the nineties to noughties and beyond Surgeon 2018 16 350 4 10.1016/j.surge.2018.03.006 29680182

48. Shoemaker ML White MC Wu M Weir HK Romieu I Differences in breast cancer incidence among young women aged 20–49 years by stage and tumor characteristics, age, race, and ethnicity, 2004–13 Breast Cancer Res Treat 2018 169 595 606 10.1007/s10549-018-4699-9 29445940 PMC5955792

49. Brinton LA Sherman ME Carreon JD Anderson WF Recent trends in breast cancer among younger women in the United States J Natl Cancer Inst 2008 100 1643 8 10.1093/jnci/djn344 19001605 PMC2720764

50. DeSantis CE Ma J Jemal A Trends in stage at diagnosis for young breast cancer patients in the United States Breast Cancer Res Treat 2019 173 743 7 10.1007/s10549-018-5042-1 30426307

51. Glass AG Lacey JV Jr. Carreon JD Hoover RN Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status J Natl Cancer Inst 2007 99 1152 61 10.1093/jnci/djm059 17652280

52. Guo F Kuo YF Berenson AB Breast cancer incidence by stage before and after change in screening guidelines Am J Prev Med 2019 56 100 8 10.1016/j.amepre.2018.08.018 30573138 PMC6312406

53. Guo F Kuo YF Shih YCT Giordano SH Berenson AB Trends in breast cancer mortality by stage at diagnosis among young women in the United States Cancer 2018 124 3500 9 10.1002/cncr.31638 30189117 PMC6191354

54. Heer E Ruan Y Mealey N Quan ML Brenner DR The incidence of breast cancer in Canada 1971-2015: trends in screening-eligible and young-onset age groups Can J Public Health 2020 111 787 93 10.17269/s41997-020-00305-6 32144720 PMC7501384

55. Hou N Huo D A trend analysis of breast cancer incidence rates in the United States from 2000 to 2009 shows a recent increase Breast Cancer Res Treat 2013 138 633 41 10.1007/s10549-013-2434-0 23446808

56. Johnson RH Chien FL Bleyer A Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009 J Am Med Assoc 2013 309 800 5 10.1001/jama.2013.776 23443443

57. Li CI Daling JR Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004 Cancer Epidemiol Biomark Prev 2007 16 2773 80 10.1158/1055-9965.EPI-07-0546 18086787

58. Smigal C Jemal A Ward E Cokkinides V Smith R Howe HL Trends in breast cancer by race and ethnicity: update 2006 CA Cancer J Clin 2006 56 168 83 10.3322/canjclin.56.3.168 16737949

59. Thomas A Rhoads A Pinkerton E Schroeder MC Conway KM Hundley WG Incidence and survival among young women with stage I-III breast cancer: SEER 2000–2015 JNCI Cancer Spectr 2019 3 pkz040 10.1093/jncics/pkz040 31392297 PMC6668585

60. Aarts MJ van der Aa MA Coebergh JW Louwman WJ Reduction of socioeconomic inequality in cancer incidence in the South of the Netherlands during 1996–2008 Eur J Cancer 2010 46 2633 46 10.1016/j.ejca.2010.07.039 20843492

61. Bouchardy C Usel M Verkooijen HM Fioretta G Benhamou S Neyroud-Caspar I Changing pattern of age-specific breast cancer incidence in the Swiss canton of Geneva Breast Cancer Res Treat 2010 120 519 23 10.1007/s10549-009-0478-y 19633953

62. Colonna M Delafosse P Uhry Z Poncet F Arveux P Molinie F Is breast cancer incidence increasing among young women? An analysis of the trend in France for the period 1983–2002 Breast 2008 17 289 92 10.1016/j.breast.2007.10.017 18053721

63. Forjaz de Lacerda G Kelly SP Bastos J Castro C Mayer A Mariotto AB Breast cancer in Portugal: temporal trends and age-specific incidence by geographic regions Cancer Epidemiol 2018 54 12 8 10.1016/j.canep.2018.03.003 29544153 PMC5971140

64. Katalinic A Rawal R Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy Breast Cancer Res Treat 2008 107 427 30 10.1007/s10549-007-9566-z 17453336

65. Kvale R Myklebust TA Engholm G Heinavaara S Wist E Moller B Prostate and breast cancer in four Nordic countries: a comparison of incidence and mortality trends across countries and age groups 1975–2013 Int J Cancer 2017 141 2228 42 10.1002/ijc.30924 28795403

66. Leclere B Molinie F Tretarre B Stracci F Daubisse-Marliac L Colonna M Trends in incidence of breast cancer among women under 40 in seven European countries: a GRELL cooperative study Cancer Epidemiol 2013 37 544 9 10.1016/j.canep.2013.05.001 23768969

67. Louwman WJ Voogd AC van Dijck JA Nieuwenhuijzen GA Ribot J Pruijt JF On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975–2004: a long-term population-based study in southeastern Netherlands Cancer Causes Control 2008 19 97 106 10.1007/s10552-007-9075-8 18038250

68. Merlo DF Ceppi M Filiberti R Bocchini V Znaor A Gamulin M Breast cancer incidence trends in European women aged 20-39 years at diagnosis Breast Cancer Res Treat 2012 134 363 70 10.1007/s10549-012-2031-7 22456983

69. Pollan M Pastor-Barriuso R Ardanaz E Arguelles M Martos C Galceran J Recent changes in breast cancer incidence in Spain, 1980–2004 J Natl Cancer Inst 2009 101 1584 91 10.1093/jnci/djp358 19861303 PMC2778670

70. Bravo LE Garcia LS Carrascal E Rubiano J Burden of breast cancer in Cali, Colombia: 1962–2012 Salud Publica Mex 2014 56 448 56 10.21149/spm.v56i5.7370 25604291 PMC7282241

71. King SC Pollack LA Li J King JB Master VA Continued increase in incidence of renal cell carcinoma, especially in young patients and high grade disease: United States 2001 to 2010 J Urol 2014 191 1665 70 10.1016/j.juro.2013.12.046 24423441 PMC4479175

72. Nepple KG Yang L Grubb RL 3rd Strope SA Population based analysis of the increasing incidence of kidney cancer in the United States: evaluation of age specific trends from 1975 to 2006 J Urol 2012 187 32 8 10.1016/j.juro.2011.09.028 22088338

73. Palumbo C Pecoraro A Rosiello G Luzzago S Deuker M Stolzenbach F Renal cell carcinoma incidence rates and trends in young adults aged 20–39 years Cancer Epidemiol 2020 67 101762 10.1016/j.canep.2020.101762 32585430

74. Tyson MD Humphreys MR Parker AS Thiel DD Joseph RW Andrews PE Age-period-cohort analysis of renal cell carcinoma in United States adults Urology 2013 82 43 7 10.1016/j.urology.2013.02.065 23706585

75. De P Otterstatter MC Semenciw R Ellison LF Marrett LD Dryer D Trends in incidence, mortality, and survival for kidney cancer in Canada, 1986–2007 Cancer Causes Control 2014 25 1271 81 10.1007/s10552-014-0427-x 25034462 PMC4194017

76. Temkin SM Kohn EC Penberthy L Cronin KA Rubinsak L Dickie LA Hysterectomy-corrected rates of endometrial cancer among women younger than age 50 in the United States Cancer Causes Control 2018 29 427 33 10.1007/s10552-018-1018-z 29497884

77. Lindemann K Eskild A Vatten LJ Bray F Endometrial cancer incidence trends in Norway during 1953–2007 and predictions for 2008–27 Int J Cancer 2010 127 2661 8 10.1002/ijc.25267 20162667

78. Duncan ME Seagroatt V Goldacre MJ Cancer of the body of the uterus: trends in mortality and incidence in England, 1985–2008 BJOG 2012 119 333 9 10.1111/j.1471-0528.2011.03201.x 22082282

79. Scott OW Tin Tin S Bigby SM Elwood JM Rapid increase in endometrial cancer incidence and ethnic differences in New Zealand Cancer Causes Control 2019 30 121 7 10.1007/s10552-019-1129-1 30671687

80. Gad MM Saad AM Al-Husseini MJ Abdel-Gawad YM Alsalhani OM Alhaddad R Temporal trends of pancreatic ductal adenocarcinoma in young adults in the United States: a population-based study Clin Res Hepatol Gastroenterol 2020 44 204 10 10.1016/j.clinre.2019.07.001 31420297

81. Gordon-Dseagu VL Devesa SS Goggins M Stolzenberg-Solomon R Pancreatic cancer incidence trends: evidence from the surveillance, epidemiology and end results (SEER) population-based data Int J Epidemiol 2018 47 427 39 10.1093/ije/dyx232 29149259 PMC5913617

82. Tavakkoli A Singal AG Waljee AK Elmunzer BJ Pruitt SL McKey T Racial disparities and trends in pancreatic cancer incidence and mortality in the United States Clin Gastroenterol Hepatol 2020 18 171 8 e110 10.1016/j.cgh.2019.05.059 31202981

83. Zhang J Dhakal I Yan H Phillips M Kesteloot H Registries SC Trends in pancreatic cancer incidence in nine SEER cancer registries, 1973–2002 Ann Oncol 2007 18 1268 79 10.1093/annonc/mdm123 17488731

84. Zhong YJ Wen YF Wong HM Yin G Lin R Yang SY Trends and patterns of disparities in burden of lung cancer in the United States, 1974–2015 Front Oncol 2019 9 404 10.3389/fonc.2019.00404 31214489 PMC6555199

85. Jemal A Center MM Ward E The convergence of lung cancer rates between blacks and whites under the age of 40, United States Cancer Epidemiol Biomark Prev 2009 18 3349 52 10.1158/1055-9965.EPI-09-0740 19959681

86. Henley SJ Richards TB Underwood JM Eheman CR Plescia M McAfee TA Lung cancer incidence trends among men and women—United States, 2005–9 MMWR Morb Mortal Wkly Rep. 2014 63 1 5 24402465 PMC5779336

87. Linares I Molina-Portillo E Exposito J Baeyens JA Suarez C Sanchez MJ Trends in lung cancer incidence by histologic subtype in the south of Spain, 1985-2012: a population-based study Clin Transl Oncol 2016 18 489 96 10.1007/s12094-015-1392-x 26329296

88. Al-Husseini MJ Kunbaz A Saad AM Santos JV Salahia S Iqbal M Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: a SEER-based analysis BMC Cancer 2019 19 46 10.1186/s12885-019-5267-3 30630456 PMC6327491

89. Palumbo C Pecoraro A Rosiello G Luzzago S Deuker M Stolzenbach F Bladder cancer incidence rates and trends in young adults aged 20-39 years Urol Oncol 2020 38 934 e911 934 e919 10.1016/j.urolonc.2020.06.009 32653412

90. Polednak AP Recent trends in incidence rates for selected alcohol-related cancers in the United States Alcohol Alcohol 2005 40 234 8 10.1093/alcalc/agh150 15797879

91. Braakhuis BJ Leemans CR Visser O Incidence and survival trends of head and neck squamous cell carcinoma in the Netherlands between 1989 and 2011 Oral Oncol 2014 50 670 5 10.1016/j.oraloncology.2014.03.008 24735546

92. Braakhuis BJ Visser O Leemans CR Oral and oropharyngeal cancer in The Netherlands between 1989 and 2006: Increasing incidence, but not in young adults Oral Oncol 2009 45 e85 89 10.1016/j.oraloncology.2009.03.010 19457708

93. Islami F DeSantis CE Jemal A Incidence trends of esophageal and gastric cancer subtypes by race, ethnicity, and age in the United States, 1997-2014 Clin Gastroenterol Hepatol 2019 17 429 39 10.1016/j.cgh.2018.05.044 29902641

94. Anderson WF Camargo MC Fraumeni JF Jr. Correa P Rosenberg PS Rabkin CS Age-specific trends in incidence of noncardia gastric cancer in US adults J Am Med Assoc 2010 303 1723 8 10.1001/jama.2010.496 PMC3142962 20442388

95. Anderson WF Rabkin CS Turner N Fraumeni JF Jr. Rosenberg PS Camargo MC The changing face of noncardia gastric cancer incidence among US non-Hispanic Whites J Natl Cancer Inst 2018 110 608 15 10.1093/jnci/djx262 29361173 PMC6005150

96. Merchant SJ Kim J Choi AH Sun V Chao J Nelson R A rising trend in the incidence of advanced gastric cancer in young Hispanic men Gastric Cancer 2017 20 226 34 10.1007/s10120-016-0603-7 26924751 PMC5630456

97. Wang Z, El-Serag HB, Thrift AP. Increasing incidence of advanced non-cardia gastric cancers among younger Hispanics in the USA. Dig Dis Sci. 2020;66:1669–72. 10.1007/s10620-020-06397-x 32548813

98. Song M Kang D Yang JJ Choi JY Sung H Lee Y Age and sex interactions in gastric cancer incidence and mortality trends in Korea Gastric Cancer 2015 18 580 9 10.1007/s10120-014-0411-x 25091081

99. Trivers KF Sabatino SA Stewart SL Trends in esophageal cancer incidence by histology, United States, 1998-2003 Int J Cancer 2008 123 1422 8 10.1002/ijc.23691 18546259

100. Gilhodes J Belot A Bouvier AM Remontet L Delafosse P Ligier K Incidence of major smoking-related cancers: trends among adults aged 20–44 in France from 1982 to 2012 Cancer Epidemiol 2015 39 707 13 10.1016/j.canep.2015.07.001 26209939

101. Cabasag CJ Arnold M Butler J Inoue M Trabert B Webb PM The influence of birth cohort and calendar period on global trends in ovarian cancer incidence Int J Cancer 2020 146 749 58 10.1002/ijc.32322 30968402 PMC6786921

102. Kim SI Lim MC Lim J Won YJ Seo SS Kang S Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012 J Gynecol Oncol 2016 27 e5 10.3802/jgo.2016.27.e5 26463436 PMC4695455

103. Saad El Din K Loree JM Sayre EC Gill S Brown CJ Dau H Trends in the epidemiology of young-onset colorectal cancer: a worldwide systematic review BMC Cancer 2020 20 288 10.1186/s12885-020-06766-9 32252672 PMC7137305

104. Shah TA Guraya SS Breast cancer screening programs: review of merits, demerits, and recent recommendations practiced across the world J Microsc Ultrastruct 2017 5 59 69 10.1016/j.jmau.2016.10.002 30023238 PMC6025760

105. Schreuders EH Ruco A Rabeneck L Schoen RE Sung JJ Young GP Colorectal cancer screening: a global overview of existing programmes Gut 2015 64 1637 49 10.1136/gutjnl-2014-309086 26041752

106. Oke JL O’Sullivan JW Perera R Nicholson BD The mapping of cancer incidence and mortality trends in the UK from 1980-2013 reveals a potential for overdiagnosis Sci Rep. 2018 8 14663 10.1038/s41598-018-32844-x 30279510 PMC6168593

107. Lew JB St John DJB Macrae FA Emery JD Ee HC Jenkins MA Benefits, harms, and cost-effectiveness of potential age extensions to the national bowel cancer screening program in Australia Cancer Epidemiol Biomark Prev 2018 27 1450 61 10.1158/1055-9965.EPI-18-0128 30190276